Wednesday, July 8, 2026

biotech · Non-Small Cell Lung Cancer · Pneumococcal Vaccines · MAIA

MAIA Biotechnology

Makai Biotechnology is a biotech organization headquartered in honolulu, USA. It trades on NYSE under ticker MAIA. Primary therapeutic focus areas include Non-Small Cell Lung Cancer, Pneumococcal Vaccines, Carcinoma, Non

honolulu, USA HQ
2013 Founded
5 Employees
Public company Type
MAIA · NYSE Ticker
Company details
Clinical program

12-Valent Pneumococcal Conjugate Vaccine

Phase 3 · mab · Pneumococcal Vaccines

12-Valent Pneumococcal Conjugate Vaccine for Pneumococcal Vaccines is a Phase 3 program (mab) at MAIA Biotechnology with 1 ClinicalTrials.gov record(s).

Internal code Protocol ASCLIN 002/2022

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
MAIA Biotechnology
Phase
Phase 3
Modality
mab
Indication
Pneumococcal Vaccines
Status
active
Trials
1